Form 4: Elanco EVP Modi Acquires Future Stock Units

Elanco Animal Health's EVP, Rajeev A. Modi, reported the acquisition of 63.8655 deferred stock units, effective October 31, 2025, under a Rule 10b5-1 plan.

Summary

• Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), reported an acquisition of deferred stock units.
• The transaction date for the acquisition is October 31, 2025.
• Mr. Modi acquired 63.8655 Deferred Stock Units (DSUs).
• Each DSU represents the right to receive one share of Company common stock or its cash equivalent.
• The implied price per DSU at the time of acquisition was $22.15.
• Following this transaction, Mr. Modi beneficially owns 7,163.1698 DSUs.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• DSUs are scheduled to settle in cash or shares of common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 6

Explanation: Slightly positive due to an executive's acquisition of company stock (even if deferred and future-dated), indicating continued alignment of interests, and the use of a 10b5-1 plan for transparency.

Positives

• The acquisition of deferred stock units by a key executive, even if future-dated, indicates continued alignment of management's interests with shareholder value.
• The transaction was conducted under a Rule 10b5-1 plan, which demonstrates a pre-planned and transparent approach to insider trading, reducing concerns about opportunistic timing.

Negatives

• The relatively small number of units acquired (63.8655) may not significantly impact the executive's overall compensation structure or signal a strong conviction in the company's immediate short-term performance.

Risks

• The value of the deferred stock units is tied to the future performance of Elanco's common stock, exposing the executive to market fluctuations until settlement.
• Future changes in the company's Executive Deferral and Stock Match Plan could alter the terms or timing of DSU settlement.

Future Outlook

The deferred stock units are scheduled to settle in cash or shares of Elanco common stock following the termination of employment or during a specified future year, in accordance with the company's Executive Deferral and Stock Match Plan.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically an executive's acquisition of deferred stock units. Such transactions are common mechanisms for executive compensation and long-term incentive alignment across various industries, including animal health. It does not directly reflect broader industry trends but rather internal compensation strategies.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through equity ownership. The use of a 10b5-1 plan provides transparency regarding future transactions.
• Employees: The transaction is part of an executive compensation plan, which may set a precedent or reflect the company's broader approach to incentivizing key personnel.

Next Steps

• Settlement of the deferred stock units in cash or shares of common stock upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Key Dates

Keywords

Elanco Animal Health, ELAN, Rajeev A. Modi, Form 4, Insider Trading, Deferred Stock Units, DSU, Executive Compensation, Rule 10b5-1, Stock Acquisition, Officer Transaction